Advanced and experienced hematology and cancer care.
Advanced and experienced hematology and cancer care.
Current Trials


  • Phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease
  • Postmenopausal female patients
  • ER- and/or PgR+ plus HER2- status
  • No more than 1 previous line of therapy
  • At least one measurable non-visceral lesion


  • Observational study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Care
  • Non-Interventional
  • Approved first, second, or third line therapies
  • Observational study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Care.
  • Non-Interventional


  • AM0010 in combination with Pembrolizumab vs. Pembrolizumab alone as first line therapy in patients with stage IV/metastatic NonSmall Cell Lung Cancer and tumors with high expression of PD-L1
  • Patients with tumor tissue high expression of PD-L1 as defined by Tumor Proportion Score (TPS) ≥ 50% and as determined by a FDA approved test PD-L1 IHC 22C3 assay is mandatory.
  • Patients without known EGFR or EML4-ALK mutation
  • Patients must be naïve to therapy for the advanced stage (Stage IIIb or IV) of the disease. Previous neoadjuvant or adjuvant therapy is allowed for patients who successfully underwent complete radical surgery and ONLY if the last treatment was administered more than 12 months prior to the start of the trial treatment.

Multiple Myeloma

  • A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  • Relapsed MM
  • Measurable disease w/ at least 1 of the following:
  • Immunoglobulin G (IgG) MM: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
  • IgA, IgD, IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL
  • urine M-protein ≥ 200 mg per 24 hours in subjects without detectable serum or urine M-protein, serum free light chain (SFLC) ≥ 100  mg(involved light chain) and an abnormal serum kappa lambda ratio.
  • Approved first, second and third line treatments  

Febrile Neutropenia

  • Estimate the incidence of FN among subjects treated with myelosuppressive chemotherapy for the treatment of non-myeloid malignancies and receiving Neulasta Onpro kit, Neulasta Onpro kit with every administered chemotherapy cycle, or other physician choice options for FN prophylaxis
  • Biopsy-proven breast cancer, lung cancer, NHL or prostate cancer patients starting myelosuppressive chemo neoadjuvant/adjuvant or first line setting with at least 4 anticipated chemotherapy cycles.
  • Recently started myelosuppressive chemotherapy < 7 Days with high FN risk > 20%, or intermediate FN risk 10-20%.